The Ameliorative Effect of CPCC and Role of CRT in Hepatic Injury by Alloxan-Treatment

Abstract:

The objective of this study is to examine the protection effect of CPCC treatment in hepatic injury and the role of Calreticulin (CRT) in hepatic injury. The control and alloxan groups were given water and the CPCC group was given CPCC (Cr3+40μg/kg.d) every day, respectively. After 4 weeks, the alloxan and CPCC groups were injected with alloxan (40mg/kg) for 6d. Total protein was extracted from mice liver. SDS-PAGE and two-dimensional electrophoresis (2-DE) were performed in this study from the total protein of mice hepatic. The samples of 2-DE were analyzed through Time of Flight Mass Spectrometer . The mRNA of CRT was detected using fluorescence quantitative polymerase chain reaction (qPCR) in mice liver. The results of 2-DE and qPCR showed the expression of CRT had significant difference among controlalloxan and CPCC mice both on the transcriptional and protein levels. CRT is a potential target as the roles of treatment and prevention in hepatic injury. CPCC is expected to become new health product for prevention and treatment of the hepatic injury.

• Periodical: Advanced Materials Research (Volumes 690-693)
• Pages: 1404-1409
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.690-693.1404
• Online since: May 2013
• Authors: Hong Mei Yuan, Dong Feng Ming, Shu Qing Ma, Wei Jiang Fan
• Keywords: Alloxan, Calreticulin (CRT), Collagen Protein-Chromium (III) Complex (CPCC), Hepatic Injury

References

[1] Liu anjun, wang xiuli, chen ying, zhang guorong: Acta Nutrimenta Sinica 2006; 28: 487–493.(in chinese)

[2] Camacho P, Lechleiter JD: Cell; 1995; 82(5):765–771.

[3] Oyadomari S, Takeda K, Takiguchi M, Gotoh T, Matsumoto M, Wada I, Akira S, Araki E, Mori M: Proc Natl Acad Sci USA; 2001; 98(19):10845–10850.

DOI: 10.1073/pnas.191207498

[4] Hung CC, Ichimura T, Stevens JL, Bonventre JV: J Biol Chem; 2003; 278(31):29317–29326.

[5] Tan Y, Chen M, Li Z, Mabuchi K, Bouvier M: Biochim Biophys Acta; 2006; 1760(5):745–753.

[6] Ellgaard L, Frickel EM: Cell Biochem Biophys; 2003;39(3):223-47.

[7] Steinø A, Jørgensen CS, Laursen I, Houen G: Scand J Immunol; 2004; 59(5):485–495.

[8] Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S, Walsh K: J Clin Invest; 2007; 117(2):375–386.

DOI: 10.1172/jci29709